Document Detail


Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes.
MedLine Citation:
PMID:  20920046     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
We compared the combined use of basal insulin, metformin and insulin secretagogues with a combination of basal insulin and metformin in patients with type 2 diabetes starting basal insulin analogue therapy. This analysis was part of a 24-week trial, in which 964 insulin-naive patients with type 2 diabetes inadequately controlled on oral agents (including metformin) were randomized to insulin glargine or detemir. Secretagogues were stopped or maintained at the site-investigators' discretion. During the study, 57.6% of patients continued their secretagogue treatment. Compared with patients stopping secretagogues, those who continued experienced significantly more hypoglycaemia and weight gain. Insulin doses, however, were significantly lower: 0.6 ± 0.4 versus 0.8 ± 0.4 U/kg/day (p < 0.001). The difference between groups in mean HbA1c reduction was not statistically significant. In conclusion, in type 2 diabetic patients starting basal insulin analogue therapy, continuing both metformin and secretagogues results in more hypoglycaemia and weight gain and lower insulin doses than only maintaining metformin.
Authors:
S G Swinnen; M-P Dain; D Mauricio; J H DeVries; J B Hoekstra; F Holleman
Related Documents :
17403126 - A randomized controlled trial examining combinations of repaglinide, metformin and nph ...
9194536 - Effects of insulin and the combination of insulin plus metformin (glucophage) on microv...
11087006 - Optimising therapy for insulin-treated type 2 diabetes mellitus.
16996226 - Thiazolidinedione anti-cancer activity: is inhibition of microtubule assembly implicated?
1344296 - The effect of transplantation site and islet mass on long-term survival and metabolic a...
17426086 - Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient wo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  12     ISSN:  1463-1326     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  923-5     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens...
Next Document:  Level of concern and precaution taking among Australians regarding travel during pandemic (H1N1) 200...